MicroPort Scientific (HK:0853) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
MicroPort Scientific’s subsidiary, Shanghai MicroPort Endovascular MedTech, reported a significant financial performance for the first nine months of 2024, with a 9.13% increase in revenue and a 40.82% rise in profit compared to the same period last year. The net profit attributable to equity owners surged by 42.46%, indicating strong growth potential for investors. Despite the impressive results, investors are advised to consider these figures cautiously as they offer a limited view of the company’s overall operations.
For further insights into HK:0853 stock, check out TipRanks’ Stock Analysis page.
